系统性红斑狼疮患者超低分割全乳放疗后出现重度急性放射性皮炎
一例76岁女性,临床静止期SLE/Sjögren综合征,长期服用吗替麦考酚酯,左乳浸润性导管癌(ER/PR阳性、HER2阴性,pT1cN0(sn),IA期)保乳术后接受26 Gy/5次全乳三维适形放疗。约2周后出现RTOG 3级急性放射性皮炎,经局部及支持治疗恢复延长,后风湿科评估示全身症状复发需贝利尤单抗。作者指出虽无法证实因果,但该严重度对FAST-Forward方案不典型,提示SLE相关放射敏感性可能参与。
要点
- SLE合并慢性DMARD治疗者全乳超低分割放疗证据稀少,需多学科评估与明确告知。
- 本例26 Gy/5次后出现RTOG 3级急性放射性皮炎,恢复延长。
- 现代数据示结缔组织病非乳腺放疗绝对禁忌,低分割可feasible,但超低分割需谨慎。
核心结论
- 虽不能证明因果,但该例急性皮炎严重度对FAST-Forward全乳照射不典型,提示SLE相关放射敏感性可能参与。
- 现代数据表明结缔组织病并非乳腺放疗绝对禁忌,低分割可行。
- SLE接受慢性DMARD治疗者全乳超低分割放疗证据稀疏,需多学科评估、明确告知并系统报告严重毒性。
研究设计与样本
- 本文为单例临床场景报告(Pract Radiat Oncol),描述一例76岁临床静止期SLE/Sjögren综合征、长期服用吗替麦考酚酯的早期左乳癌患者接受超低分割全乳放疗后的重度急性毒性及处理。
主要发现
- 患者左乳浸润性导管癌ER/PR阳性、HER2阴性,13 mm 3级肿瘤伴淋巴血管侵犯、切缘阴性、0/5前哨淋巴结,pT1cN0(sn),IA期。
- 放疗采用仰卧野中野三维适形,26 Gy/5次全乳照射,未行区域淋巴结照射及瘤床加量;PTV V95% 95%,最大剂量104.9%,平均心脏剂量0.8 Gy,同侧肺V8 Gy 15%。
- 约放疗后2周出现进行性红斑、弥漫性乳腺水肿、疼痛及超出皮肤皱褶的广泛融合性湿性脱屑,无感染证据,符合RTOG 3级急性放射性皮炎。
- 处理包括局部糖皮质激素、磺胺嘧啶银、酶藻酸盐凝胶、聚合物膜敷料、镇痛、密切护理随访及后续淋巴水肿导向物理治疗,恢复延长。
- 后续风湿科再评估记录全身症状复发,需贝利尤单抗治疗。
关键数值与推荐
- 急性放射性皮炎分级采用RTOG标准,本例为3级。
- 放疗剂量与分割:26 Gy分5次照射左全乳。
- 剂量学参数:PTV V95% 95%,最大剂量104.9%,平均心脏剂量0.8 Gy,同侧肺V8 Gy 15%。
临床怎么用
- SLE患者尤其长期DMARD治疗者行乳腺放疗前应多学科评估并明确告知超低分割证据有限。
- 在肿瘤学可接受时,可考虑中等低分割或缩小照射体积以降低毒性风险。
- 对严重毒性应系统报告,以便积累SLE患者超低分割放疗的安全性数据。
局限性
- 单例报告,无法证明SLE相关放射敏感性与重度皮炎的因果关系。
- SLE接受慢性DMARD治疗者全乳超低分割放疗证据稀疏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whole-breast ultra-hypofractionated radiation therapy is an accepted adjuvant option for early-stage breast cancer, but evidence remains limited for patients with systemic lupus erythematosus (SLE), particularly those receiving chronic disease modifying antirheumatic drug (DMARD) therapy. CLINICAL SCENARIO: A 76-year-old woman with clinically quiescent SLE/Sjögren syndrome on mycophenolate mofetil was diagnosed with left breast invasive ductal carcinoma, ER/PR-positive and HER2-negative. After breast-conserving surgery and sentinel lymph node biopsy, pathology showed a 13-mm grade 3 tumor with lymphovascular invasion, negative margins, and 0/5 sentinel nodes, pT1cN0(sn), stage IA. Radiation omission was considered because of age, node-negative disease, and planned endocrine therapy; however, grade 3 histology, lymphovascular invasion, and Ki-67 of 43% placed her outside the lowest-risk populations supporting omission. During a period of active regional conflict with daily missile threats, an expedited regimen was selected. She received 26 Gy in 5 fractions to the left whole breast using supine field in-field 3-dimensional conformal radiation therapy, without regional nodal irradiation or tumor-bed boost. Dosimetry was acceptable, with PTV V95% 95%, maximum dose 104.9%, mean heart dose 0.8 Gy, and ipsilateral lung V8 Gy 15%. OUTCOME: Approximately 2 weeks after treatment, she developed progressive erythema, diffuse breast edema, pain, and extensive confluent moist desquamation beyond skin folds, without evidence of infection, consistent with RTOG grade 3 acute radiation dermatitis. Management included topical corticosteroids, silver sulfadiazine, enzyme alginogel, polymeric membrane dressings, analgesics, close nursing follow-up, and subsequent lymphedema-directed physiotherapy. Recovery was prolonged, and later rheumatologic reassessment documented recurrent systemic symptoms requiring belimumab. CONCLUSION: Although causality cannot be proven, the severity of acute dermatitis was atypical for FAST-Forward whole-breast irradiation and suggests that SLE-associated radiosensitivity may have contributed. Modern data indicate that connective tissue disease is not an absolute contraindication to breast radiation, and hypofractionation can be feasible. However, evidence is sparse for whole-breast ultra-hypofractionation in patients with SLE on chronic DMARD therapy. Multidisciplinary assessment, explicit counseling, consideration of moderate hypofractionation or reduced-volume treatment when oncologically acceptable, and systematic reporting of severe toxicity are warranted.
引用
- Melotek JM, Moshe AB, Gerber NK, et al. Severe Acute Radiation Dermatitis Following Ultra-Hypofractionated Whole Breast Radiation Therapy in a Patient With Systemic Lupus Erythematosus. Pract Radiat Oncol. 2026. PMID: 42722231. doi:10.1016/j.prro.2026.08.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。